From the Journals

New Vaccine Prevents Severe RSV Illness

A recent study showed the new vaccine was more than 90% effective in the prevention of hospitalizations and emergency department visits due to RSV among those 60 years old or older.

Share

A large-scale study conducted at Kaiser Permanente Southern California found that the respiratory syncytial virus prefusion F vaccine was 91% effective at preventing RSV-related hospitalizations and emergency department visits among adults aged 60 years and older. The retrospective case-control study analyzed data from 7,047 lower respiratory tract disease encounters, and the researchers found an adjusted vaccine effectiveness of 91%. Vaccinating approximately 250 persons could prevent one RSV-related emergency department visit or hospitalization in the first season after vaccination. The study represented the first major real-world effectiveness analysis of RSVpreF vaccination since its licensure in 2023.

Original Source(s)

New Vaccine Prevents Severe RSV Illness

A recent study showed the new vaccine was more than 90% effective in the prevention of hospitalizations and emergency department visits due to RSV among those 60 years old or older.

  • by Kerri Miller

  • December 13, 2024

  • 2 min

Related Content

Personalizing Steroid Duration in Asthma

Researchers tested whether a readily available biomarker can individualize systemic corticosteroid prescribing during asthma-related hospitalizations.

A Persistent Cough and an Unexplained Diagnosis

NEJM case details the diagnostic evaluation of an 80-year-old woman with weeks of respiratory symptoms, weight loss, and diffuse ground-glass opacities on chest CT.

Most Long COVID Cases Persist Beyond 2 Years

In a three-year follow-up study, fewer than 2% of long COVID cases reported resolution of symptoms, with vaccinated patients demonstrating significantly better physical and mental health outcomes.